SARTORIUS
At today’s Sartorius AG Annual Shareholders’ Meeting in Goettingen, Germany, shareholders approved the board's proposals by a large majority. The Annual Shareholders' Meeting thus passed the resolution to pay dividends of 0.46 euros per preference share (previous year 0.381 euros) and 0.45 euros per ordinary share (previous year 0.371 euros). The total amount disbursed will rise by 20.5 % year over year from 25.8 million euros to 31.1 million euros. At 23.5 %, the payout ratio is at the level of the previous years (2015: 24.0 %).
During the regular election of shareholder representatives to the Supervisory Board, shareholders re-elected Dr. Lothar Kappich, Prof. Dr. Dres. h.c. Arnold Picot, Prof. Dr. Thomas Scheper and Prof. Dr. Klaus Rüdiger Trützschler. Dr. Daniela Favoccia, Partner of the lawyer’s office Hengeler Mueller, and Ilke Hildegard Panzer, Executive Vice President and Chief Innovation Officer of the BloodCenter of Wisconsin, part of the US-based Health Care-company Versiti Inc., were elected for the first time. The new Supervisory Board will serve for a term of five years.
Furthermore, the Annual Shareholders' Meeting granted discharge to the Supervisory Board and to the Executive Board by a considerable majority. On the whole, more than 500 share owners representing over 96 % of the voting share capital attended this year's Annual Shareholders' Meeting.
1 Adjusted for stock split; rounded values
This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.
Presentation Held by Dr. Joachim Kreuzburg at the Annual Shareholders' Meeting
You will find this presentation and further information on the ASM at: https://www.sartorius.com/sartorius/en/EUR/company/investor-relations/sartorius-ag/shareholders-meeting/2017
Current Image Files
Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG
www.sartorius.com/fileadmin/media/global/company/Sartorius_Kreuzburg.jpg
Sartorius products used in the manufacture of medications
https://www.sartorius.com/mediafile/corp/Sartorius_0232_PG9_01_RGB.jpg
Sartorius products used in biopharma research laboratories
www.sartorius.com/mediafile/corp/Sartorius_0424_PG14.jpg
Upcoming Financial Dates
April 24, 2017 Publication of first-quarter figures (January to March 2017)
July 25, 2017 Publication of the first-half figures (January to June 2017)
October 24, 2017 Publication of nine-month figures (January to September 2017)
A Profile of Sartorius
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. Approximately 7,000 people work at the Group's approximately 50 manufacturing and sales sites, serving customers around the globe.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170406005678/en/
Contact:
Sartorius
Petra Kirchhoff, Vice President of Corporate
Communications
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 20256.5.2025 08:00:00 CEST | Press release
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies Agendia®, Inc., today announced that new data from its ongoing FLEX Study will be presented at the upcoming ESMO BreastCancer 2025 congress taking place May 14-17 in both Munich, Germany and virtually. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505212759/en/ The FLEX Study (NCT03053193) is a prospective real-world evidence, observational breast cancer study designed to correlate whole transcriptome gene expression in early-stage breast cancer with clinical outcomes, and to evaluate how genomic insights can inform treatment decisions in early-stage breast cancer. In this analysis, researchers examined the impact of BluePrint, Agendia’s 80-gene molecular subtyping assay, on pathological complete response (pCR) rates and chemothera
Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x6.5.2025 06:15:00 CEST | Press release
K Navigator increases researcher productivity by 20x¹, accelerating biomedical breakthroughs and outperforming leading generalist LLMs Analyzes and visualizes multimodal patient data, plus exclusive access to MOSAIC Window, a subset of the world’s largest spatial omics dataset in oncology Built by biologists, for biologists. Free to use for academic researchers.² Owkin, a leading agentic AI company, has launched K Navigator, an AI-powered research co-pilot designed to revolutionize biomedical science. K Navigator is an agentic playground where researchers can explore, refine, and validate hypotheses, accelerating the quality and pace of their discoveries. With K Navigator, Owkin moves closer to its vision of developing the world’s first Biological Artificial Superintelligence (BASI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505282917/en/ K Navigator home screen. A single natural language interface - K Navigator enab
NIKE, Inc. Announces Senior Leadership Changes to Accelerate Growth and Drive Win Now Action Plan5.5.2025 22:15:00 CEST | Press release
Amy Montagne Becomes President, NikePhil McCartney Becomes EVP, Chief Innovation, Design & Product OfficerNicole Graham Becomes EVP, Chief Marketing OfficerTom Clarke Becomes Chief Growth Initiatives OfficerHeidi O’Neill to Retire NIKE, Inc. (NYSE:NKE) announced a series of strategic changes to its Senior Leadership Team (SLT), elevating experienced leaders to accelerate progress against its Win Now action plan to position the company for future growth. Elliott Hill, President and CEO, NIKE, Inc. and Heidi O’Neill, President of Consumer, Product, and Brand, have decided the Consumer, Product, and Brand leadership will now be divided into three distinct areas: Consumer and Sport, Marketing, and Product Creation, inclusive of Innovation and Design. These roles will now report directly to Hill. As a result of these changes O’Neill has decided to retire from Nike after 26 years. She will continue to serve in an advisory capacity until September 2025. “For nearly three decades, Heidi has be
LR Health & Beauty Once Again Demonstrates Its Expertise in Aloe Vera5.5.2025 16:24:00 CEST | Press release
The social commerce company develops a unique combination of Aloe Vera Gel and fermented Aloe LR Health & Beauty has been synonymous with the best Aloe Vera quality on the market for over 20 years, and continuously invests in new product innovations to take full advantage of the plant's range of beneficial properties. The majority of the over 60 products are developed and produced directly at the company headquarters in Ahlen. LR has now made a decisive breakthrough in skin care cosmetics with its unique combination of pure Aloe Vera leaf gel and fermented Aloe Vera. The care products with the highest Aloe Vera content therefore not only work in the upper and middle layers of the skin, but also unleash the full potential of Aloe Vera in the deeper layers. The effectiveness of this LR Aloe Via Magic Power Duo has been confirmed by the dermatological institute, Dermatest. All the products tested based on a combination of Aloe Vera Gel and fermented Aloe were awarded the 5-star "very good
MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets5.5.2025 16:09:00 CEST | Press release
The largest tokenization initiative of its kind comes ahead of the $MBG token launch, paving the way for regulated digital access to prime property assets MultiBank Group, the world’s largest financial derivatives institution based in Dubai has signed a historic $3 billion tokenization agreement with MAG, the leading real estate developer in the UAE, and Mavryk, a leading blockchain innovator — marking the largest real-world asset (RWA) tokenization initiative globally to date. The initiative highlights the imminent launch of $MBG, the utility token at the core of MultiBank’s next-generation digital finance ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505317631/en/ MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets The partnership will bring MAG’s high-value real estate developments — The Ritz-Carlton Residences, Dubai, Creekside, which is part of the Keturah Resort
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom